Effect of treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) on coronary plaque progression: a serial CT angiography study
| Autor: | Jean-Claude Tardif, Reda Ibrahim, Josephine Pressacco, Jean Grégoire, Suguru Matsumoto, Philippe L. L’Allier, Matthew J. Budoff |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Time Factors
Computed Tomography Angiography 030204 cardiovascular system & hematology Cardiorespiratory Medicine and Haematology Imaging 0302 clinical medicine Clinical trials Oral administration Coronary plaque 80 and over Medicine Hydroxyurea acute coronary syndromes 030212 general & internal medicine Lipoxygenase Inhibitors Prospective Studies Plaque Atherosclerotic Aged 80 and over medicine.diagnostic_test General Medicine Middle Aged Coronary Vessels Plaque Atherosclerotic Treatment Outcome Atreleuton Cardiology Disease Progression Radiology medicine.symptom Drug Cardiology and Cardiovascular Medicine Adult medicine.medical_specialty Acute coronary syndrome Ischemic heart disease Clinical Investigations Inflammation and over Placebo Dose-Response Relationship 03 medical and health sciences Internal medicine Multidetector Computed Tomography Humans Acute Coronary Syndrome Aged Dose-Response Relationship Drug business.industry computed tomography medicine.disease Clinical trial Cardiovascular System & Hematology Angiography business Follow-Up Studies |
| Zdroj: | Clinical cardiology, vol 40, iss 4 Matsumoto, S; Ibrahim, R; Gregoire, JC; L'Allier, PL; Pressacco, J; Tardif, J-C; et al.(2017). Effect of treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) on coronary plaque progression: a serial CT angiography study. CLINICAL CARDIOLOGY, 40(4), 210-215. doi: 10.1002/clc.22646. UCLA: Retrieved from: http://www.escholarship.org/uc/item/9f65w0rm |
| DOI: | 10.1002/clc.22646. |
| Popis: | BACKGROUND: Inflammation has a key role in the process of atherosclerosis. Production of leukotrienes by 5‐lipoxygenase has been linked to atherosclerotic plaques and cardiovascular events. HYPOTHESIS: In this study, a selective 5‐LO inhibitor will slow plaque progression using serial cardiac computed tomographic angiography (CCTA). METHODS: Patients with recent acute coronary syndrome (ACS) were prospectively assigned to one of 3 VIA‐2291 doses (25 mg, 50 mg, 100 mg) or placebo by oral administration. All groups underwent CCTA at baseline and at 6 months’ follow‐up. Plaque types such as low‐attenuation plaque (LAP), fibro‐fatty tissue (FF), fibro‐calcified plaque (FC), and dense calcium plaque (DC) were measured based upon predefined density threshold, and changes from baseline CCTA were analyzed. RESULTS: The final analysis included 54 patients (age, 56 ± 9 years; 85.1% male) with CCTA at baseline and 24 weeks. Evaluating on treatment VIA‐2291 (all 3 doses, n = 37) demonstrated significant reductions in plaque progression compared with placebo (n = 17). VIA‐2291 significantly reduced LAP (5.9 ± 20.7 mm(3) vs −9.7 ± 33.3 mm(3)), FF (11.1 mm(3) ± 13.3 mm(3) vs −0.9 ± 2.7 mm(3)), and FC (−0.1 ± 6.22 mm(3) vs −14.3 ± 6.2 mm(3); all P < 0.05) and retarded the progression of DC (3.9 ± 3.2 mm(3) vs 0.2 ± 0.4 mm(3)) compared with placebo. CONCLUSIONS: VIA‐2291 resulted in slowed plaque progression compared with placebo across different plaque subtypes in patients with recent ACS (http://ClinicalTrials.gov NCT00358826). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|